Roche Inks $15B ADC Pact with Hansoh; Veradermics Scores in Another Baldness Study
Hansoh gets $400 million upfront and could earn more than $15 billion in milestones as Roche takes global rights outside Greater China.
10 Articles
10 Articles
China’s Hansoh Pharma strikes drug deal with Roche worth over $15 billion - Regional Media News
By Nichiket Sunil and Patrick Wingrove Oct 19 (Reuters) - China's Hansoh Pharmaceutical said on Monday it has entered into a partnership and licensing deal with Roche potentially worth more than $15 billion that covers a portfolio of antibody-drug conjugate programs. As part of the [...]
Roche is expanding its collaboration with China's Hansoh Pharmaceutical in a deal that could be worth more than $15 billion, about SEK 150 billion, plus royalties. The deal includes several early-stage cancer projects and marks a continued growing interest in Chinese drug development.
$15 billion deal: Roche bets on China — and questions Germany’s future - European Biotechnology Magazine
The Swiss pharmaceutical group has agreed to another, deeper ADC partnership with China’s Hansoh Pharma, with potential milestone payments exceeding $15 billion. The deal comes amid mixed developments: While China wants to do more to protect its biotech technologies from flowing abroad, Roche’s new investment decisions in Germany are on hold for now.
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
